Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors (Q39333633)

11 September 2017

Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors (English)

1 reference

11 September 2017

1

1 reference

11 September 2017

9

1 reference

Laura Cristina Luna Oliva

11 September 2017

Enrico Milan

4

0 references

series ordinal

2

object named as

Laura Oliva

1 reference

11 September 2017

3

Fulvia Cerruti

1 reference

11 September 2017

5

Giada Bianchi

1 reference

11 September 2017

7

Alexandre Mezghrani

1 reference

11 September 2017

8

Elena Pasqualetto

1 reference

11 September 2017

Mary Raule

6

1 reference

PubMed ID

22685320

11 September 2017

Paolo Cascio

series ordinal

10

1 reference

11 September 2017

8 June 2012

1 reference

Journal of Leukocyte Biology

11 September 2017

1 reference

11 September 2017

92

1 reference

11 September 2017

921-931

1 reference

11 September 2017

5

1 reference

Quantifying the contribution of defective ribosomal products to antigen production: a model-based computational analysis

11 September 2017

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Quantitating protein synthesis, degradation, and endogenous antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Proteostenosis and plasma cell pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Proteasome inhibitor therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Dangerous small B-cell clones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Amyloidosis: pathogenesis and new therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Protein degradation and protection against misfolded or damaged proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

The 26S proteasome: a molecular machine designed for controlled proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Dampening Ab responses using proteasome inhibitors following in vivo B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Progressively impaired proteasomal capacity during terminal plasma cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Managing and exploiting stress in the antibody factory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Enhanced expression of interferon-gamma-induced antigen-processing machinery components in a spontaneously occurring cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Preparation of hybrid (19S-20S-PA28) proteasome complexes and analysis of peptides generated during protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Rapid degradation of a large fraction of newly synthesized proteins by proteasomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

The proteasome in terminal plasma cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Impairment of the ubiquitin-proteasome system by protein aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Cysteinyl-tRNA deacylation can be uncoupled from protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

RNA binding targets aminoacyl-tRNA synthetases to translating ribosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Innate immune and chemically triggered oxidative stress modifies translational fidelity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Proteasomes in immune cells: more than peptide producers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Early events in spontaneous neutrophil apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Role of the CC chemokine receptor 9/TECK interaction in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

Protein homeostasis and aging: taking care of proteins from the cradle to the grave

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1011497

21 January 2018

Identifiers

DOI

10.1189/JLB.1011497

1 reference

11 September 2017

1 reference

PubMed ID

22685320